24/7 Wall Street
17 Sept 2026, 13:50 UTC · 1h ago
Verdict
Headline leans bullish. We score MRNA +0.90 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.90strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish · 0 new · 4 priced in
Moderna's Phase 2b adjuvant melanoma data showed a 49% reduction in recurrence risk or death versus KEYTRUDA alone.
Priced inreported in August / presented at ASCO 2026
So whatThis catalyst drove a 137% monthly gain, shifting the valuation multiple toward oncology optionality.
More positive than 98% of claims this week
Moderna guided to an interim analysis from its Phase 3 adjuvant melanoma trial in the second half of 2026.
Continue reading
5 related stories
More positive than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inmentioned on the second-quarter call
So whatA positive readout within the next few months would validate the Phase 2b data and accelerate the path to commercialization.
More positive than 91% of claims this week
Moderna guided to up to 10% revenue growth and year-end cash of $4.7 billion to $5.2 billion for 2026.
Priced inguidance provided in second-quarter call
So whatThe ~ $5B cash floor limits dilution risk for the remaining 2026 pipeline spend.
More positive than 65% of claims this week
BioNTech is seeing limited market read-through from Moderna's results due to differences in tumor biology and indications.
Priced instated on the second-quarter call
More negative than 66% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
Stock has surged 137% in a month due to highly positive Phase 2b melanoma vaccine data.
More positive than 58% of ticker scores this week
Partner on a successful individualized neoantigen program showing a 49% reduction in recurrence risk.
More positive than 52% of ticker scores this week
Experienced a modest 'sympathy bid' as a general vaccine-sector name.
More positive than 46% of ticker scores this week
Stock edged up slightly, but the market is showing a muted response compared to Moderna.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
20h ago
More positive than 56% of relationship scores this week
[mutual] Both companies run rival individualized mRNA cancer vaccine programs.
+10.1%
Price agrees with the score
$160.37 vs $145.62 close before publication (Sep 16) · not market-adjusted
MRNA chart →
